A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Amgen

Status and phase: Completed; Phase 4

Conditions: Hyperparathyroidism; Parathyroid Neoplasms

Treatments: Drug: AMG 073

Study type: Interventional

Funder types: Industry

Identifiers

NCT00037518

20000204

Details and patient eligibility

About

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; * Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; * Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)